Specifying the Anti-inflammatory Effects of Ziltivekimab (SPIDER)
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2/3. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting Amsterdam UMC
- Trial code
- EU 2024-515893-29-01
- Record updated
- 2024. november 19.
- Original description
The objective of this study is to research whether ziltivekimab therapy for 20 weeks reduces arterial wall inflammation, as assessed by state-of-the-art imaging modalities, and reduces systemic inflammatory tone, as assessed by in depth phenotyping of circulating monocytes, inflammatory biomarkers and proteomics.Read full original descriptionShow less
Specifying the anti-inflammatory effects of ziltivekimab with diverse imaging modalities and in-depth cellular phenotyping (SPIDER)
The objective of this study is to research whether ziltivekimab therapy for 20 weeks reduces arterial wall inflammation, as assessed by state-of-the-art imaging modalities, and reduces systemic inflammatory tone, as assessed by in depth phenotyping of circulating monocytes, inflammatory biomarkers and proteomics.
Inclusion: Age 50 years and older; Multi-vessel coronary artery disease (defined as CAD-RADS ≥2 and/or PAV/NCPV stage ≥2); Serum hsCRP level ≥2 mg/L.
Exclusion: Chronic or recent (<1 month) (serious) infections and/or clinical signs of acute (serious) infection; History of severe auto-immune diseases, or other (severe) (recurrent or chronic) inflammatory disorders; Untreated latent tuberculosis, active hepatitis B (positive HBsAg and/or positive anti-HBc with detectable HBV DNA) or C, human immunodeficiency virus (HIV) not on stable antiretroviral regimen; Coronary stents in situ.